Chiusura precedente | 26,23 |
Aperto | 26,14 |
Denaro | 23,37 x 100 |
Lettera | 23,48 x 100 |
Min-Max giorno | 23,23 - 26,14 |
Intervallo di 52 settimane | 13,36 - 27,50 |
Volume | |
Media Volume | 363.246 |
Capitalizzazione | 701,996M |
Beta (5 anni mensile) | -0,31 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -6,08 |
Prossima data utili | 05 ago 2024 - 09 ago 2024 |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | 45,44 |
SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced two upcoming presentations at the 32nd European Academy of Dermatology and Venerology (EADV) Congress in Berlin, Germany, Oct. 11-14, 2023. The oral presentation will focus on ANB032’s previously reported healthy volunteer Phase 1 data and the trial-in-progress poster presentation will focus on ANB032’s Phas
Webcast at 4:15pm ET/1:15pm PT on Wednesday, Oct. 25 SAN DIEGO, Oct. 09, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it will host a virtual R&D event for the investment community on rosnilimab, a PD-1 agonist antibody, at 4:15pm ET/1:15pm PT on Wednesday, Oct. 25. Independent medical experts and members of Anaptys senior management will discuss: PD-1 biology and rosnilim
53.3% of patients who received a single dose of 750mg IV imsidolimab achieved GPPPGA 0/1 (clear or almost clear) at Week 4 (primary endpoint), compared to 13.3% of patients on placebo (p=0.0131)Demonstrated favorable safety and tolerability with no SAEs, low incidence and no increase of infections vs. placebo and no cases of DRESS or Guillain-Barre in imsidolimab-treated patientsOnly one of 30 (3.3%) imsidolimab-treated patients had detectable ADA, which were non-neutralizingPlan to present comp